CD8A and neoplasm: Additionally, research has shown that patients with locally advanced ESCC undergoing chemoradiotherapy, when radiating more than 50% tumor‐draining lymph nodes (TDLNs), which is crucial for the production of tumor‐specific CD8+ effector T cells [10], can lead to immune suppression and poor overall survival [11].